Welcome reception

Welcome and introductions
Saad Usmani 

Session 1: Defining high-risk multiple myeloma (part I)
Chairs: Kenneth Anderson & Martin Kaiser

• A T-cell signature identifying HR patients in MM: Chng Wee Joo
• The detection of PR cells at single cell level identifies high risk disease in myeloma: Paola Neri
• Genomic profile of high-risk MM without t(4;14) and del17p: Mehmet Samur

Panel discussion

Session 2: Defining high-risk multiple myeloma (part II)
Chairs: Lawrence Boise & Leif Bergsagel

• Metabolic vulnerabilities in t(14;16) MM: Chng Wee Joo
• Triggering immunogenic cell death to overcome high-risk MM: Kenneth Anderson
• High-risk multiple myeloma in the immunotherapy era: Francesco Maura
• Definition and outcomes of high-risk multiple myeloma in recent clinical trials: Martin Kaiser

Panel discussion

 

Break

 

Session 3: Circulating malignant plasma cell biology
Chairs: Paola Neri & Niels Weinhold

• Transcriptional drivers of aggressive clinical behaviour: Gareth Morgan
• Elevated circulating tumor cell numbers associate with a highly proliferative and genomically complex phenotype in newly-diagnosed multiple myeloma patients: Juan José Garcés

Panel discussion

Session 4: Extramedullary disease biology
Chairs: Benjamin Barwick & Maximillian Merz

• High-risk features of bone marrow-independent disease: Niels Weinhold
• Extramedullary disease versus paraskeletal disease – is there a biological difference?: Saurabh Zanwar
• Overcoming spatial sampling bias by liquid biopsy: Johannes Waldschmidt

Panel discussion

Lunch

 

Session 5: MMSET disease subset
Chairs: Mattia D’Agostino & Francesco Maura

• Enhancing glucocorticoid activity in multiple myeloma: Jonathan Licht
• Prognostic impact of t(4;14), alone and in combination with other genomic risk factors: Kylee Maclachlan
• Pharmacologic and phenotypic targeting of t(4;14) MM: Benjamin Barwick
• Functional genomics studies to define therapeutic targets for high-risk MM: Constantine Mitsiades

Panel discussion

Session 6: Immuno- and targeted therapies and data in high risk
Chairs: Ross Firestone & Sham Mailankody

• Targeting GPRC5D: Outcomes in high-risk subgroups: Ajai Chari
• Role of ADCs in the management of high-risk myeloma: Nisha Joseph
• Multiple antigen targeting to overcome resistance to T cell redirecting therapy for high risk myeloma: Peter Voorhees

Panel discussion

Break

Session 7: CAR therapies and data in high risk
Chairs: Nizar Bahlis & Samir Parekh

• Defining high-risk multiple myeloma in the era of CAR T-cell therapy: Sham Mailankody
• Optimizing CAR T-cell therapy for high-risk multiple myeloma: Doris Hansen
• Allo and in vivo: Off-the-shelf cell therapies for multiple myeloma: Karlo Perica

Panel discussion

Session 8: Resistance to immuno- and targeted therapies in high risk
Chairs: Peter Voorhees & Ajai Chari

• Novel myeloid-derived resistance mechanisms for CAR-T/TCE therapies: Samir Parekh
• Resistance to bispecific antibodies, focus on genomics: Holly Lee
• Resistance to bispecific antibodies, focus on high-risk immune profile: Ross Firestone

Panel discussion

Day 1 conclusions
Saad Usmani

Faculty dinner

Welcome to Day 2
Saad Usmani

Session 9: MAF/MAFB disease
Chairs: Hira Mian & Brian Walker

• Exploring the oncogenic MAF protein interactome: Anastasios Karadimitris
• Modeling high risk MM genetic and immune features in mice: José Martínez-Climent
• Detecting all patients with MAF dysregulation using clinical whole genome sequencing: Jonathan Keats
• Novel biomarkers for guiding the use of immunotherapies: Frank Zhan

Panel discussion

Session 10: Designing single-arm studies in high-risk MM
Chairs: Marta Chesi & Martin Kaiser

• Preclinical optimization of TCE in multiple myeloma: Marta Chesi
• Bispecific antibody-based approaches to HRMM: Marc Raab
• Innovative trial designs for high risk myeloma: Sham Mailankody
• Leveraging consistent profiling for single-arm trials with external comparators: Martin Kaiser

Panel discussion

Break

Session 11: Designing randomized studies in high-risk MM
Chairs: Robert Orlowski & Ajai Nooka

• Importance of translational studies in clinical trials of HRMM: Maximillian Merz
• Talk title TBC: Robert Orlowski
• Role of MRD in randomized trials: Francesca Gay
• Optimizing the timing of immunotherapy in randomized trials for high-risk myeloma: Binod Dhakal

Panel discussion

Meeting conclusions and close
Saad Usmani

Lunch and adjourn